Search results for "PARKINSON'S"
showing 10 items of 232 documents
Life-Space Mobility in Parkinson's Disease: Associations with Motor and Non-Motor Symptoms.
2019
Background To describe life-space mobility and explore associations of motor and non-motor symptoms with life-space mobility in people with Parkinson’s disease (PD). Methods About 164 community-dwelling persons with PD (mean age 71.6 years, 64.6% men) received a postal survey and a subsequent home visit. Motor assessments included perceived walking difficulties (Walk-12G), mobility (Timed Up and Go test), motor symptoms (UPDRS-III), and freezing of gait (item 3, FOG-Qsa). Non-motor symptoms included depressive symptoms (GDS-15), pain, fatigue (NHP-EN), and global cognition (MoCA). Life-space mobility was assessed with the life-space assessment (LSA). Calculations included composite score (r…
A system-level mathematical model of Basal Ganglia motor-circuit for kinematic planning of arm movements
2017
International audience; In this paper, a novel system-level mathematical model of the Basal Ganglia (BG) for kinematic planning, is proposed. An arm composed of several segments presents a geometric redundancy. Thus, selecting one trajectory among an infinite number of possible ones requires overcoming redundancy, according to some kinds of optimization. Solving this optimization is assumed to be the function of BG in planning. In the proposed model, first, a mathematical solution of kinematic planning is proposed for movements of a redundant arm in a plane, based on minimizing energy consumption. Next, the function of each part in the model is interpreted as a possible role of a nucleus of…
Frequency-specific network activity predicts bradykinesia severity in Parkinson’s disease
2021
Highlights • Parallel subnetworks are affected in bradykinesia. • The primary motor and the premotor cortex are common nodes with task-specificity. • Beta activity decreases, gamma activity increases with improvement of bradykinesia. • Subthalamic stimulation reduces beta, increases gamma power in ipsilateral cortex. • Subnetworks act with frequency-specific oscillations.
Neuroprotection in Parkinson's Disease: a Realistic Goal?
2010
The current issue of CNS Neuroscience & Therapeutics contains an interesting review by Kinecses and Vecsei [1] on the progress in our knowledge related to the pathophysiological mechanisms of Parkinson's disease (PD) and on the development of putative neuroprotective molecules. Since the seminal discovery by Oleh Hornykiewicz that degeneration of DA neurons within the substantia nigra pars compacta (SNc) and the consequential dopamine depletion in the striatum was the cause of neurological symptoms in PD [2], thousands of reviews have been written on the subject, some of them possibly superfluous. Nevertheless, we found this last work enjoyable in terms of readability and in the way the aut…
Impairment of Methylation cycle in treated patients with Parkinson's disease
2008
L-3,4-dihydroxyphenylalanine (L-DOPA) alone or in combination with a peripheral dopa decarboxylase inhibitor (DDI) is the most effective therapeutic agent to improve motor function in most of patients with Parkinson's disease (PPD). However, chronic L-DOPA therapy is associated with of side-effects arising particularly during long-term therapy. Only a small percentage of an exogenous dose of L-DOPA is converted into dopamine (DA) in the brain. The majority is either decarboxylated in peripheral tissues by aromatic amino acid decarboxylase (AAD) to DA, which does not cross the blood-brain barrier, or is O-methylated by catechol-O-methyltransferase (COMT) in both peripheral and brain tissue t…
Predictors of caregiver burden in partners of patients with Parkinson's disease
2009
Music therapy in Parkinson's disease
2014
Linguistic, psychometric validation and diagnostic ability assessment of an Italian version of a 19-item wearing-off questionnaire for wearing-off de…
2012
Urinary dysfunction in Parkinson’s disease patients
2016
Background: Autonomic nervous system dysfunction that affects 70–80% of Parkinson’s disease (PD) patients, causes significant morbidity and it is correlated with poor quality of life. Objective: We assessed in a consecutive series of PD patients frequency of autonomic symptoms by means of the Scale for Outcomes for Parkinson’s disease AUTonomic (SCOPA-AUT) and we correlated it with the results of noninvasive urological studies (nUS). Methods: PD patients with known conditions that might have influenced urinary function were excluded. Clinical assessment of PD patients included the H&Y staging, UPDRS, BDI, NPI, PDQ- 39, PDSS, ESS, and the SCOPA-AUT scale. nUS consisted of uroflowmetry an…